Why IMU is a multi multi bagger, page-12538

Imugene is presenting a poster at the forthcoming AACR Annual Meeting in Orlando 19th April 2023.

6788 / 4 - hNIS imaging data from a first-in-human trial of the oncolytic virus CF33-hNIS-antiPD-L1 in patients with triple negative breast cancer

https://www.abstractsonline.com/pp8/#!/10828/presentation/4773

Results: From October 2021 to October 2022, 8 patients were enrolled in this ongoing study and received at least 1 dose of CF33-hNIS-anti-PD-L1 injection at one of the first 3 dose levels (1 x 10⁵, 3 x 10⁵, or 1 x 10⁶ PFU). All 8 patients underwent SPECT imaging at C1D8 with 6/8 patients (75%) having uptake at the site of injection on the SPECT imaging study. Four of 4 patients (100%) with injection sites at metastatic subcutaneous nodules, intramuscular masses, or axillary lymph nodes and 2/4 patients (50%) with injection sites at matted dermal metastatic lesions had uptake on SPECT.

.